News

The trial was designed to explore the safety and tolerability of PBT2, and its effects on the mechanism and progression of the disease, by investigating biomarkers of Alzheimer’s

Nastech’s intellectual property estate includes rights to issued and pending patent applications relating to RNA-based therapeutics which have broad claims on their development, delivery and use in treating

The technology protected under the patent relates to specific methods for enhancing antigen-specific T-helper cell stimulation using small synthetic peptides. Both prophylactic and immunotherapeutic vaccine peptides are currently

Ethicon Endo-Surgery has agreed to pay Cyberonics a signing fee of $9.5 million and royalties on commercial sales of products covered by the subject patents. Dan Moore, president

Kuvan is an oral small molecule for the treatment of phenylketonuria (PKU) developed in partnership with Merck Serono. The terms of the agreement specify a reduction in royalties

The trial involves approximately 160 migraine patients with or without aura. Three doses of AZ-104 (1.25mg, 2.5mg and 5mg) were evaluated against placebo in the clinical trial. Using

This Phase II study is the first in a number of further clinical studies planned for the anticancer vascular-disrupting agent CYT997 and will be conducted at the Alfred

In June 2006, GlaxoSmithKline’s (GSK’s) Center of Excellence for External Drug Discovery and Galapagos initiated a program to deliver disease-modifying drugs with clinical proof of concept to GSK’s

According to RaySearch, Compass is a state-of-the-art solution for quality assurance in radiotherapy used to measure and reconstruct the 3D radiation dose that was actually delivered to the